Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, has announced that its representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. This forum provides a platform for experts in nasal drug development to discuss innovations, and Silo's involvement signals its strategic focus on advancing its lead candidate, SPC-15, which utilizes a nose-to-brain approach for the targeted delivery of therapeutics to treat post-traumatic stress disorder (PTSD).
CEO Eric Weisblum emphasized the importance of the forum for engaging with key opinion leaders and industry peers as Silo continues to progress SPC-15 through the development pipeline. The company recently reported preclinical data demonstrating that the SPC-15 formulation and its delivery device met predefined specifications for assay, impurities, pH, and microbiological quality through nine months. Additionally, six-month accelerated stability data were consistent and aligned with long-term stability findings, indicating the product's robustness and potential for commercial viability.
The IPAC-RS (International Pharmaceutical Aerosol Consortium on Regulation & Science) Nasal Innovation Forum is a key event for stakeholders involved in nasal drug product development, bringing together regulatory, scientific, and industry experts. Silo's participation highlights the company's dedication to advancing innovative drug delivery mechanisms that could offer new treatment options for underserved conditions like PTSD, which affects millions worldwide and currently has limited effective therapies.
Silo Pharma is a diversified biopharmaceutical and cryptocurrency treasury company with a therapeutic focus on stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Its portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company collaborates with leading universities and laboratories to conduct its research, aiming to bring novel treatments to patients with high unmet needs.
The forum participation comes at a time when the company is making significant strides in its development efforts. The stability data for SPC-15 are crucial for regulatory filings and eventual commercialization. According to the company, the data support the feasibility of the nose-to-brain delivery approach, which has the potential to improve patient outcomes by enhancing drug bioavailability and reducing systemic side effects.
Investors and industry watchers will be keenly observing Silo's progress as it engages with the scientific community at the forum. The company's participation is expected to foster collaborations and knowledge exchange that could accelerate the development of SPC-15 and other pipeline assets. For more information about Silo Pharma, visit the company's website at silopharma.com.
For the latest news and updates relating to SILO, refer to the company's newsroom at https://ibn.fm/SILO.
